Teva Pharmaceutical Industries Limited (NYSE:TEVA) Position Trimmed by Continental Advisors LLC

Continental Advisors LLC reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 5.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 341,118 shares of the company's stock after selling 20,500 shares during the quarter. Teva Pharmaceutical Industries accounts for approximately 3.5% of Continental Advisors LLC's holdings, making the stock its 6th biggest holding. Continental Advisors LLC's holdings in Teva Pharmaceutical Industries were worth $7,518,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in TEVA. FMR LLC boosted its holdings in Teva Pharmaceutical Industries by 30.7% in the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock valued at $1,806,910,000 after purchasing an additional 19,242,468 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after acquiring an additional 4,418,961 shares during the period. Lingotto Investment Management LLP increased its stake in Teva Pharmaceutical Industries by 2.6% during the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock worth $599,320,000 after purchasing an additional 688,862 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Teva Pharmaceutical Industries by 2.2% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company's stock valued at $573,822,000 after purchasing an additional 569,412 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Teva Pharmaceutical Industries by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 9,281,052 shares of the company's stock worth $203,642,000 after acquiring an additional 489,041 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. Barclays cut their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. UBS Group reduced their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Bank of America reduced their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Finally, StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA traded up $0.42 during trading on Thursday, hitting $14.71. 8,358,482 shares of the company were exchanged, compared to its average volume of 9,938,244. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a 52-week low of $12.47 and a 52-week high of $22.80. The company has a market cap of $16.68 billion, a PE ratio of -10.14, a P/E/G ratio of 1.44 and a beta of 0.72. The stock has a 50 day moving average of $15.26 and a 200 day moving average of $17.58.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.